GNPS - Randomized clinical trial for the treatment of moderate to severe cases of the disease caused by the new coronavirus-2019 with chloroquine and placebo versus chloroquine and colchicine

Evaluate efficacy and safety of the use of chloroquine and colchicine in the treatment of hospitalized patients for moderate or severe forms of SARS-CoV-2. Draw a clinical and laboratory profile of the disease in our country. Assess the magnitude of systemic inflammation and possible pathophysiological mechanisms of SARS-CoV-2. The IRB approval number is 30248420.9.0000.5440 (University of Sao Paulo, Brazil)